# Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.

> **NCT05288478** · PHASE2 · UNKNOWN · sponsor: **University of Chile** · enrollment: 100 (estimated)

## Conditions studied

- Epidermolysis Bullosa
- Oral Ulcer

## Interventions

- **COMBINATION_PRODUCT:** Dentoxol mouthrinse dosages

## Key facts

- **NCT ID:** NCT05288478
- **Lead sponsor:** University of Chile
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-06
- **Primary completion:** 2022-08
- **Final completion:** 2023-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288478, "Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05288478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*